B Cell News and Research

RSS

COX-2 inhibitor extends sunitinib activity in renal cell carcinoma

The effectiveness of sunitinib for the treatment of renal cell carcinoma could be enhanced with the addition of a cyclooxygenase-2 inhibitor, study findings show.

20 Feb 2013

Metastatic tumors best for sunitinib response evaluation in mRCC

When evaluating treatment response in non-nephrectomized patients with metastatic renal cell carcinoma, the primary lesion does not have to be selected as the target lesion, researchers report.

20 Feb 2013

Possible alternative to biopsy discovered for renal cancer diagnosis

Combining positron emission tomography scanning with iodine-124 (124I)–girentuximab may offer an effective noninvasive method of diagnosing clear cell renal cell carcinoma in patients who present with a renal mass, US study results suggest.

20 Feb 2013

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

20 Feb 2013

Study demonstrates function of newly discovered regulatory mechanism of myeloid cells in cancer

Researchers at the Moffitt Cancer Center have found a potential mechanism by which immune suppressive myeloid-derived suppressor cells can prevent immune response from developing in cancer.

20 Feb 2013

Healthy adults with shorter telomere length more likely to develop upper respiratory infection

Among healthy adults who were administered a cold virus, those with shorter telomere length (a structure at the end of a chromosome) in certain cells were more likely to develop experimentally-induced upper respiratory infection than participants with longer telomeres, according to results of preliminary research published in the February 20 issue of JAMA.

20 Feb 2013

Scientists demonstrate advantages of wavelength-modulated Raman spectroscopy

Raman spectroscopy has enabled incredible advances in numerous scientific fields and is a powerful tool for tissue classification and disease recognition, although there have been considerable challenges to using the method in a clinical setting. Scientists have now demonstrated the advantages of wavelength-modulated Raman spectroscopy, opening the door to wider biomedical and clinical applications such as real-time assessment of tissues during surgery.

20 Feb 2013

CINJ researcher receives PCF grant for study on lung cancer detection and prevention

Sharon Pine, PhD, a researcher at The Cancer Institute of New Jersey and assistant professor of medicine at the University of Medicine of Dentistry of New Jersey-Robert Wood Johnson Medical School has been awarded a two-year, $80,000 dollar research grant from the Prevent Cancer Foundation.

20 Feb 2013

J Cell Mol Med, Microbial Biotechnology join Wiley Open Access publishing program

John Wiley & Sons, Inc., announced today that Journal of Cellular and Molecular Medicine and Microbial Biotechnology have joined the Wiley Open Access publishing program. All articles in these two journals are now open access and free to view, download and share.

20 Feb 2013

Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene

Inspiration Biopharmaceuticals and Ipsen today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation.

20 Feb 2013

Immature malaria parasites more resistant to treatment with artemisinin

New research has revealed that immature malaria parasites are more resistant to treatment with key antimalarial drugs than older parasites, a finding that could lead to more effective treatments for a disease that kills one person every minute and is developing resistance to drugs at an alarming rate.

20 Feb 2013

Study may help design better DAA drug cocktails to treat HCV

Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) agent in development for the treatment of HCV, targets one of the HCV proteins (i.e., NS5A) and causes the fastest viral decline (within 12 hours of treatment) ever seen with anti-HCV drugs.

20 Feb 2013

TIR-199 shows promise in fighting renal cancer

Chemists at the University of California, Riverside have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer.

20 Feb 2013

Targeting p38alpha MAPK isoform can help treat CNS inflammatory diseases

A study by a leading Alzheimer's researcher at the University of Kentucky provides new evidence that will help researchers home in on the molecular mechanisms involved in inflammation of the central nervous system (CNS) and aid drug-development strategies for treating inflammatory neurological diseases.

20 Feb 2013

Tiny microscope can help scientists observe neuronal firings in the brain

If you want to read a mouse's mind, it takes some fluorescent protein and a tiny microscope implanted in the rodent's head.

20 Feb 2013

EMA designates Osiris as Orphan Drug title holder for Prochymal

Osiris Therapeutics, Inc., the leading stem cell company developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today that the European Medicines Agency (EMA) has designated Osiris as the Orphan Drug title holder for Prochymal (remestemcel-L).

19 Feb 2013